Table 2

The characteristics of 124 patients with RA who discontinued glucocorticoids at the points of glucocorticoids initiation and discontinuation

CharacteristicsGC initiation visitGC discontinuation visitP value
Disease activity measures
 TJC284 (1–9)0 (0–2)<0.0001
 SJC283 (1–6)0 (0–1)<0.0001
 PGA, 0–10 cm5 (3–6)1 (1–3)<0.0001
 EGA, 0–10 cm5 (3–6)1 (0.5–2)<0.0001
 ESR, mm/hour37 (17–62)18 (8–29)<0.0001
 CRP, mg/dL1.28 (0.46–4.11)0.33 (0.20–0.77)<0.0001
 DAS28-ESR4.76 (3.67–5.95)2.51 (1.69–3.39)<0.0001
 SDAI18.2 (10.8–31.8)3.1 (1.8–9.0)<0.0001
 CDAI16.0 (9.0–27.0)3.0 (1.5–8.0)<0.0001
Treatment paradigm, % (n)
 MTX78.2% (97)78.2% (97)1.00
 LEF50.8% (63)50.0% (62)1.00
 HCQ51.6% (64)61.3% (76)<0.0001
 SSZ10.5% (13)11.3% (14)1.00
 TII12.1% (15)11.3% (14)1.00
 NSAIDs8.9% (11)2.4% (1)0.002
 DMARDs combination81.1% (99)81.1% (99)0.690
 Double combination55.6% (69)46.0% (57)0.570
 Triple combination24.2% (30)31.5% (39)0.495
  • CDAI, clinical disease activity index; CRP, C reactive protein; DAS28, disease activity score based on 28-joint assessment; DMARDs, disease-modifying antirheumatic drugs; EGA, evaluator’s global assessment; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PGA, patient’s global assessment; SDAI, simplified disease activity index; SJC, swollen joint count; SSZ, sulfasalazine; TII, tripterygium wilfordii Hook F; TJC, tender joint count.